ArticlePloS one2025
Pilot study: In vitro reduction of hemoglobin from canine blood with hemoperfusion using the Cytosorb® adsorber.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free hemoglobin (cfHb) can be toxic and lead to kidney injury. This study assessed the in vitro reduction of cfHb from canine hemolyzed blood using hemoperfusion with a Cytosorb® cytokine adsorber. Canine whole blood was processed in linear and circular setups, with three runs each, at 100 mL/min. Hemolysis and osmolarity adjustments were performed with distilled water and hypertonic saline. Anticoagulation was optimized with heparin (10,000 IU/L). A median of 3.38 L of hemoglobin solution was processed in the linear setup. Samples were collected after the adsorber and from the waste bag. In the circular setup, a median of 2.09 L was processed, with samples taken before and after the adsorber. CfHb concentration was measured using the XT-2000iV® hematology analyzer (Sysmex). A control setup without an adsorber was run for 24 hours to assess cfHb stability. In the linear setup, cfHb concentration decreased by a median of 17.8% (14.7-26.8%), from 1.7 mmol/L to a minimum of 0.9 mmol/L, with 12.1 g (11.9-23.5 g) of cfHb removed. The median cfHb concentration after the adsorber displayed a logarithmic increase from 0.9 mmol/L (0.8-1.2 mmol/L) to 1.6 mmol/L (1.4-2.1 mmol/L). After processing 2.4 L, no further reduction occurred. In the circular setup, cfHb was reduced by a median of 41.3% (46.1-45.0%), representing 17.4 g (14.6-19.0 g) removed after 13.0 L (13.0-14.0 L). The reduction plateau was reached after 13 L. The hemoglobin reduction ratio in the circular setup at 3 L processed cfHb-solution was 25.0% (23.1-33.3%) and was not different from the linear setup (p = 0.400). The cfHb clearance decreased in both setups over time. CfHb concentration in the control setup was stable for 24 hours. Hemoperfusion with the Cytosorb® adsorber reduced cfHb in vitro from a canine blood solution.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.